At what enterprise value was LABCO acquired in 2015?

During the acquisition of LABCO by CINVEN in 2015, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LABCO when it was acquired by CINVEN?

The estimated EV/EBITDA multiple for LABCO is in the range of 5x - 12x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was LABCO acquired by CINVEN?

LABCO was acquired by CINVEN in 2015.

What was the revenue of LABCO at the time of the deal?

The revenue of LABCO at the time of the deal is estimated to be in the range of 450M - 900M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LABCO during the acquisition?

LABCO's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LABCO acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LABCO deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.challenges.fr/economie/lead-1-cinven-confirme-l-achat-de-labco-pour-1-2-milliard_86338

← DATABASE

Home Database Healthcare & PharmaLABCO

05/2015

LABCO acquired by CINVEN

FRANCE Health Providers / Healthcare Facilities / Labs (Biology) EV 1b - 4b EUR

Context

The acquisition of Labco by funds managed by Cinven follows the strategic withdrawal of the company’s planned Initial Public Offering (IPO) on Euronext Paris. This transaction allowed for the total rationalization of a complex shareholding structure previously split between financial investors (3i, TCR Capital, NiXen, CM-CIC), founders, and a large group of independent biologists. The strategic rationale for the deal is rooted in the creation of a leading pan-European platform within the consolidating medical biology sector. By moving from a fragmented ownership model to a single institutional sponsor, the group gains the agility necessary to pursue a rapid international expansion strategy. The acquirer implemented an innovative financing structure to maintain existing bond facilities while providing immediate liquidity to the historical stakeholders. This operation took place during a record year for healthcare M&A and was designed to enhance the group's competitive positioning in bidding for hospital outsourcing contracts. The new governance model ensures long-term alignment with the group’s industrial objectives while strictly adhering to local regulatory frameworks regarding the professional ownership of medical laboratories. This partnership positions the group as a cornerstone for future consolidation in the diagnostic services market across Europe.

LABCO, which reported an EBITDA margin of LOGIN in 2014, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Labco is a leading European operator of medical diagnostic laboratories. The group manages a vast network of over 160 general and specialized laboratories, supported by more than 1,000 collection centers across seven European countries. Its medical expertise spans a wide range of clinical pathology services, including biochemistry, hematology, and high-complexity testing such as anatomical pathology, molecular genetics, and nuclear medicine. The company’s business model is based on a "hub-and-spoke" industrial strategy, consolidating local laboratories into highly automated technical platforms to serve both private patients and hospital outsourcing contracts. Strategically, Labco focuses on medical leadership and technological innovation to address the rising demand for diagnostic precision and preventive healthcare. With a workforce of over 6,000 medical and administrative professionals, the group ensures high-quality diagnostic insights through standardized processes and large-scale industrial efficiency.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2014

2013

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
08/2015	CINVEN	SYNLAB	GERMANY	Health Providers	The acquisition of Synlab by Cinven from BC Partners represents a landmark transaction in the European healthcare services sector, following closely on the heels of Cinven’s acquisition of the French group Labco
07/2015	ANTIN INFRASTRUCTURE	AMEDES	GERMANY	Health Providers	Antin Infrastructure Partners acquired a majority stake in Amedes Group from General Atlantic. The transaction provided an exit for General Atlantic, which had owned the asset since 2007 and tripled its revenues through a buy-and-build strategy (30+ acquisitions)
01/2015	CERBA HEALTHCARE	NOVESCIA	FRANCE	Health Providers	Cerba acquired 100% of Novescia. The seller was a complex consortium managed by Ekkio Capital, including financial investors Cobepa and Socadif, as well as biologist shareholders. This acquisition allowed Cerba to reach critical mass in the routine segment, complementing its leadership in specialty testing
10/2014	WATERLAND	MEDIAN KLINIKEN	GERMANY	Health Providers	Waterland Private Equity agreed to acquire 100% of MEDIAN Kliniken from Advent International and British real estate investor Marcol. Concurrently with the acquisition, Waterland announced its intention to sell MEDIAN's real estate portfolio through a sale-and-leaseback arrangement with a US real estate investor over the following months, effectively separating the operational business from its property assets
09/2014	EURAZEO	COLISÉE	FRANCE	Health Providers	The acquisition of Groupe Colisée by Eurazeo PME is a strategic move that aligns with the firm's investment strategy of supporting companies that are well-positioned to benefit from underlying societal trends
06/2014	PAI PARTNERS	DOMUSVI	FRANCE	Health Providers	PAI Partners has entered into exclusive negotiations to take control of DomusVi, the third largest French player in the private nursing home sector. Upon completion of the transaction, PAI is expected to hold 70% of the capital alongside an associated fund
03/2014	EQT PARTNERS	I-MED RADIOLOGY NETWORK	AUSTRALIA	Health Providers	The EQT Mid Market fund, alongside institutional co-investors CDPQ and GIC, acquired a majority stake in I-MED Radiology Network. The deal followed a complex period for I-MED, which had recently refinanced its debt after being controlled by a syndicate of over 40 lenders (led by Ares and Anchorage) following the global financial crisis
07/2012	MANAGEMENT & PRIVATE INVESTORS	LVL MEDICAL GERMANY	GERMANY	Health Providers	Concomitantly with the Air Liquide acquisition of LVL Médical's French activities, the Lavorel family agreed to acquire 100% of LVL Médical Allemagne from LVL Médical Groupe. The transaction was structured as a mandatory prerequisite to the Air Liquide deal, as the latter's acquisition perimeter was explicitly limited to the French operations
06/2012	AIR LIQUIDE	ORKYN (EX LVL MEDICAL)	FRANCE	Health Providers	Air Liquide entered into exclusive negotiations to acquire a controlling block of 70.49% of LVL Médical's share capital from the Lavorel family concert and other controlling shareholders. Simultaneously, the Lavorel family repurchased LVL Médical's German subsidiary for €80 million, such that Air Liquide's acquisition perimeter is limited to the French activities only
12/2010	SAGA GROUP	NESTOR HEALTHCARE GROUP	UNITED KINGDOM	Health Providers	Saga acquired 100% of Nestor Healthcare Group via a public takeover. The acquisition establishes Saga as a nationwide home care provider by combining Nestor's Northern England care network with Saga's existing Southern operations, creating full national coverage

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LABCO by CINVEN are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: cinven